Further investigations to evaluate the possible associations between PTEN loss of function and tumor grade, TIME, and whether PTEN status might influence progression and response to radiotherapy, chemotherapy, or immunotherapy in canine patients are required to assess the prognostic and therapeutic implications of decreased PTEN expression in canine gliomas. This evidence concerns the gene PTEN and glioma.